Clinical Scorecard: Anemia Tied to Higher Dementia Risk
At a Glance
Category
Detail
Condition
Anemia associated with increased risk of dementia and elevated Alzheimer disease–related biomarkers
Key Mechanisms
Anemia linked to higher levels of phosphorylated tau 217, neurofilament light chain, and glial fibrillary acidic protein indicating Alzheimer pathology, neurodegeneration, and glial activation
Target Population
Older adults aged 60 years or older without dementia at baseline
Care Setting
Clinical and research settings focusing on aging and dementia risk assessment
Key Highlights
Anemia increased dementia hazard by 66% over 9.3 years in a cohort of 2,282 older adults
Dementia risk was highest when anemia co-occurred with elevated neurodegenerative biomarkers, especially neurofilament light chain
Associations were stronger in men and modified by APOE epsilon 4 status
Guideline-Based Recommendations
Diagnosis
Assess hemoglobin levels in older adults as part of dementia risk evaluation
Measure Alzheimer disease–related blood biomarkers (p-tau217, NfL, GFAP) when feasible to identify elevated neurodegenerative risk
Management
Monitor and manage anemia in older adults to potentially reduce dementia risk
Consider sex and APOE epsilon 4 status when interpreting anemia and biomarker data
Monitoring & Follow-up
Regular follow-up of hemoglobin and cognitive status in older adults with anemia
Monitor biomarker levels if available to assess neurodegenerative progression
Risks
Anemia may reduce brain resilience, lowering threshold for clinical dementia manifestation
Normocytic anemia predominance limits understanding of other anemia subtypes' impact
Observational data do not establish causation; interpret associations cautiously
Patient & Prescribing Data
Older adults aged 60 years or older without baseline dementia
Addressing anemia may be important in dementia risk mitigation, especially in patients with elevated neurodegenerative biomarkers
Clinical Best Practices
Incorporate hemoglobin testing in routine assessments of older adults at risk for dementia
Evaluate Alzheimer disease biomarkers to stratify dementia risk when possible
Consider sex differences and APOE genotype in risk assessment and counseling
Recognize limitations of single baseline measurements and predominantly normocytic anemia in clinical interpretation
Use a multidisciplinary approach integrating hematologic and neurologic evaluations
Diffuse alveolar hemorrhage with coexistent antiphospholipid syndrome complicated anticoagulation therapy and created competing bleeding and thrombosis risks.
